Optimal Acuity Corporation

News and Events

OAC presents a retrospective observational cohort study of corneal laser procedure for vision improvement in patients with late stage wet age-related macular degeneration
23 June 2021/ Investigative Ophthalmology & Vision Science (IOVS)
A clinical study was carried out for 60 treated and 24 untreated eyes of 42 patients with wet AMD (46 treated eyes), dry AMD (8 treated eyes), or other diseases with central vision loss (6 treated eyes). Each eye received a single CPV corneal laser procedure and received pre-Tx best corrected distance visual acuity (BCDVA) and potential visual acuity (PVA) examinations and post-Tx BCDVA examinations at 1 month (1m), 3m, 6m and 12m follow-up times. 
Results: Mean (± SD) BCDVA of treated eyes improved significantly (p=0.0022) from 20/316 (1.20 logMAR) at baseline to 20/200 (1.00 logMAR) at 12m post-Tx, corresponding to 16.7 (± 9.3) letters gained. The Pearson correlation coefficient for post-Tx BCDVA logMAR values of treated eyes vs. pre-Tx PVA logMAR values were positive and large: 0.71, 0.56, 0.80 and 0.63 at 1m, 3m, 6m and 12m, respectively, indicating that the PVA test is an effective predictor of treatment outcomes. No complications or adverse events occurred.
OAC Awarded American Macular Degeneration Foundation’s Breakthrough Award

4 May 2021/ Newswise 

AC was recently awarded the Breakthrough Award of the American Macular Degeneration foundation. The American Macular Degeneration Foundation (macular.org) is a patient-centric foundation that supports potentially game-changing AMD research, education, and advocacy in order to improve quality of life and treatment outcomes for all of those affected by AMD. The award will support the next stage of clinical trials of the Clear-K® treatment. 

OAC presents a retrospective observational cohort study of corneal laser procedure for vision improvement in patients with late stage dry age-related macular degeneration

23 Dec 2020/ f1000Research 

For 32 eyes of 17 patients with late stage dry AMD; each eye received a single CPV corneal laser procedure and had 12 months (12m) post-treatment (Tx) follow-up. 

Pre- and post-Tx examinations included slit-lamp biomicroscopy, subjective manifest refraction, best corrected distance and near visual acuity (BCDVA and BCNVA), and potential visual acuity (PVA). Additional examinations including contrast sensitivity (CS), corneal topography (CT), ray tracing aberrometry (RTA) and microperimetry (MP) were obtained for a subgroup (n=12) of eyes. 

Mean (± SD) BCDVA improved significantly (p < 0.004) from 20/238 (1.08 logMAR) at baseline to 20/144 (0.86 logMAR) at 12m post-Tx corresponding to 11.0 (± 13.1) letters gained.  Mean contrast sensitivity improved significantly (p < 0.05) by a factor of 1.86 from baseline at 12m post-Tx. 

OAC presents data from dry and wet Age-Related Macular Degeneration (AMD) patients after treatment with new corneal CPV procedure for light redirections onto the retina

07 September 2017/ Acta Ophthalmologica 

Ten eyes (6 wet, 4 dry), with best-corrected near and distance visual acuities (CNVA and CDVA) between 20/80 and 20/400, without pathological retinal morphology completely affecting the central 10° (3 mm) on OCT, were given a single treatment of CPV and were examined for 12 months post-CPV. 

LogMAR Mean CNVA and CDVA in treated eyes improved (p < 0.01) from pre-CPV 0.957 and 0.942 to 0.512 and 0.638, 0.544 and 0.602, 0.531 and 0.672 at 1, 6 and 12 m, respectively. The number of ETDRS letters gained in mean binocular CNVA/CDVA were 22/15, 25/19, 25/18 at 1, 6, and 12 m, respectively. Administered NEI VFQ-25 at 3 m improved from pre-CPV. No CPV complications or adverse events occurred.